"Sidney Kimmel Cancer Center – Jefferson Health is a National Cancer Institute-designated cancer center located in Philadelphia, PA. Our mission is to improve the lives of cancer patients and their families through compassion, innovation and breakthrough discoveries."

During the past decade, Kimmel Cancer Center Thomas Jefferson University conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 8 clinical trials were completed, i.e. on average, 88.9% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 5 clinical trials were completed. i.e. 500% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kimmel Cancer Center Thomas Jefferson University" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Arch Oncology" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored, "Fox Chase Cancer Center" with 1 trials sponsored and "George E. Peoples" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kimmel Cancer Center Thomas Jefferson University" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "Hoosier Cancer Research Network" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Kimmel Cancer Center Thomas Jefferson University" are "Bladder Cancer" (2 trials), "Breast Cancer" (2 trials), "Prostate Cancer" (2 trials), "Acute Myeloid Leukemia" (1 trials) and "Adenocarcinoma of the Prostate" (1 trials). Many other conditions were trialed in "Kimmel Cancer Center Thomas Jefferson University" in a lesser frequency.

Most popular intervention types in "Kimmel Cancer Center Thomas Jefferson University" are "Drug" (12 trials), "Device" (2 trials), "Other" (2 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (4 trials), "2mg INO-5150 and electroporation device CELLECTRA®-5P" (1 trials), "2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P" (1 trials), "8.5mg INO-5150 and electroporation device CELLECTRA®-5P" (1 trials) and "8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kimmel Cancer Center Thomas Jefferson University" are 12 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Kimmel Cancer Center Thomas Jefferson University". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Kimmel Cancer Center Thomas Jefferson University, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Kimmel Cancer Center Thomas Jefferson University, 7 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".